stockrow
Friday 6 November 2026
Export ICLR’s income statement to Excel — free account
ICON PLC
ICLR Healthcare Diagnostics & Research
ICON PLC’s revenue for fiscal 2025 (year ended December 2025) was $8.3 billion, up 0.76% from fiscal 2024.
- Revenue
- −2.86%
- EPS
- +143.2%
- Free cash flow
- −8.01%
- Total debt
- −0.86%
Quarter to September 2026, against a year earlier
202.80
1.15
+0.57%
Follow ICLR
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
66.09 | 49.91 | 295.83 | 29.07 |
P/S ratio |
1.73 | 1.02 | 1.61 | 1.59 | |
P/FCF ratio |
16.58 | 11.17 | 15.10 | 15.26 | |
P/Operating CF |
61.03 | 50.74 | 47.46 | 37.89 | |
P/B ratio |
1.55 | 0.91 | 1.42 | 1.43 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
2.07 | 1.34 | 1.91 | 2.06 | |
EV/EBITDA |
20.64 | 14.48 | 23.71 | 15.62 | |
EV/Operating CF |
16.45 | 11.88 | 14.78 | 16.47 | |
EV/FCF |
19.77 | 14.63 | 17.89 | 19.75 | |
Quick Ratio |
0.72 | 0.75 | 0.66 | 0.90 | |
Current Ratio |
1.10 | 1.14 | 0.95 | 1.32 | |
Net Debt/EBITDA |
9.24 | 9.96 | 10.77 | 8.76 | |
Debt/Assets |
20.91% | 20.81% | 20.67% | 20.80% | |
Debt/Equity |
0.37 | 0.37 | 0.36 | 0.37 | |
Asset Turnover |
0.50 | 0.50 | 0.50 | 0.50 | |
Operating CF/Net income |
1.57 | 1.59 | 3.88 | 2.83 | |
Capex/Depreciation |
(0.66) | (0.34) | (0.47) | (0.40) | |
Interest Coverage |
4.20 | 3.62 | 2.83 | 3.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
8.51% | 9.86% | 9.42% | 9.72% | |
Intangible Assets out of Total Assets |
0.74 | 0.73 | 0.72 | 0.73 | |
Share Based Compensation of Revenue |
1.40% | 1.36% | 0.89% | 0.85% | |
Graham Net Nets |
(0.25) | (0.40) | (0.25) | (0.27) | |
Graham Number |
85.28 | 77.84 | 40.15 | 124.94 | |
Earnings Yield |
1.51% | 2.00% | 0.34% | 3.44% | |
Free Cash Flow Yield |
6.03% | 8.96% | 6.62% | 6.55% | |
Revenue per Share |
26.94 | 26.56 | 26.85 | 26.32 | |
Operating CF per Share |
2.99 | 2.18 | 3.66 | 4.49 | |
Capex per Share |
(0.76) | (0.40) | (0.55) | (0.49) | |
Free Cash Flow per Share |
2.23 | 1.78 | 3.11 | 3.99 | |
Cash per Share |
8.25 | 9.99 | 12.08 | 10.52 | |
Shareholders Equity per Share |
117.23 | 121.45 | 122.04 | 118.64 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
117.23 | 121.45 | 122.04 | 118.64 | |
Free Cash Flow |
174.83 | 136.24 | 238.85 | 307.15 | |
Working Capital |
305.50 | 437.80 | (186.02) | 872.72 | |
Capital Expenditures |
(59.33) | (30.77) | (42.42) | (37.99) | |
Net Current Asset Value |
(3,574.72) | (3,411.39) | (3,273.51) | (3,473.63) | |
EV/EBIT |
38.49 | 28.50 | 53.33 | 23.57 | |
Capex to Sales |
0.03 | 0.02 | 0.02 | 0.02 | |
Price to Operating Income |
32.27 | 21.75 | 45.02 | 18.21 | |
| Other line items | |||||
Average Receivables |
1,604.12 | 1,573.00 | 1,591.08 | 1,616.52 | |
Average Payables |
182.57 | 109.01 | 106.37 | 99.65 | |
Average Assets |
16,452.30 | 16,521.01 | 16,501.31 | 16,374.91 | |
Average Common Equity |
9,317.37 | 9,400.58 | 9,466.62 | 9,231.08 |
Columns are period end dates · fundamentals updated 2 Nov 2026